Dupixent’s Strong Results in Bullous Pemphigoid
Dupixent is changing how doctors think about treating bullous pemphigoid (BP), a severe skin disorder that can be hard to control. In recent studies, it emerged as the first and only biologic to show clear gains in both disease remission and symptom relief, and it performed significantly better than placebo across key measures.
ADEPT Trial: What the Data Show
The pivotal ADEPT study followed adults with moderate-to-severe BP and delivered striking findings: patients receiving Dupixent were five times more likely to achieve sustained disease remission than those on placebo. For people living with a difficult, relapsing condition, that’s a meaningful difference.
Key Results You Should Know
On the study’s primary endpoints, 20% of participants on Dupixent reached sustained disease remission at week 36, compared with 4% on placebo. Secondary outcomes echoed the same pattern, indicating benefits that stretched beyond remission to day-to-day symptom control:
- Patients with no disease relapse after corticosteroid taper: 59% on Dupixent vs. 16% on placebo (p=0.0023)
- Patients not requiring rescue therapy: 42% on Dupixent vs. 12% on placebo (p=0.0004)
- Reduction in itch severity: 52% with Dupixent vs. 27% with placebo (p=0.0021)
Taken together, these results point to a treatment that not only induces remission in more patients but also reduces the need for additional interventions and eases symptoms that can erode quality of life.
Why a Targeted Approach Matters
Dupixent blocks signaling through the interleukin?4 and interleukin?13 pathways. That’s relevant because type?2 inflammation drives BP and a number of related inflammatory diseases. In the ADEPT data, this targeted approach distinguished Dupixent from standard immunosuppressants and corticosteroids—therapies that can come with notable safety concerns and often underwhelm in older patients who may be more vulnerable to side effects.
What Experts Are Saying
Clinicians, including Dietmar Berger, M.D., Ph.D., at Sanofi, have underscored the urgency of better options for this patient group. Their view is straightforward: the ADEPT findings suggest Dupixent could shift everyday practice, offering a treatment alternative that aims at the underlying inflammatory pathways while seeking to reduce the trade-offs seen with broad immunosuppression.
Potential Impact if Approved
If regulatory reviews advance as planned, Dupixent could become the first targeted therapy approved for bullous pemphigoid in both the U.S. and the European Union. That kind of first-in-class status would likely influence how physicians sequence care—potentially moving biologic interventions earlier in the treatment journey when symptoms are most disruptive.
Dupixent already has a substantial global footprint, with approvals in more than 60 countries for conditions such as asthma, atopic dermatitis, and chronic rhinosinusitis. This real?world and clinical trial experience supports confidence in its use and may help pave the way for BP as an additional indication.
What’s Next in Research and Development
Sanofi and Regeneron, the companies behind Dupixent, continue to study its role across multiple inflammatory diseases driven by type?2 pathways. Their collaboration focuses on extending the medicine’s benefits to patient groups that still face gaps in care—and on understanding where targeted therapy can replace or reduce reliance on older, less selective treatments.
Safety and Ongoing Monitoring
Safety remains under close watch. Current studies reinforce a tolerability profile comparable to traditional treatments, and in the ADEPT trial there were no treatment?related deaths among patients receiving Dupixent. For people who struggle with the side effects of corticosteroids and immunosuppressants, that safety signal matters. It suggests a path forward for sustained disease control with fewer compromises.
The Team Behind Dupixent
Sanofi and Regeneron bring complementary strengths to the development of medicines like Dupixent. Their partnership has been central to advancing therapies for inflammatory diseases and to making these treatments available to patients who need them.
Frequently Asked Questions
What is Dupixent used for?
Dupixent treats several conditions, including asthma, atopic dermatitis, chronic rhinosinusitis, and bullous pemphigoid. Its use across these diseases reflects its focus on pathways involved in type?2 inflammation.
How effective is Dupixent in treating bullous pemphigoid?
In the ADEPT study, patients on Dupixent were five times more likely to achieve sustained disease remission than those on placebo. At week 36, 20% of Dupixent?treated patients reached sustained remission versus 4% on placebo.
Is Dupixent safe for long?term use?
Current trials support a favorable safety profile, with tolerability comparable to traditional therapies. In the pivotal trial cited here, there were no treatment?related deaths among patients receiving Dupixent.
Who makes Dupixent?
Dupixent is developed through a collaboration between Sanofi and Regeneron. Both companies contribute scientific and clinical expertise to bring new treatments to patients.
Is Dupixent approved for conditions beyond bullous pemphigoid?
Yes. Dupixent has regulatory approvals in more than 60 countries for indications such as asthma, atopic dermatitis, and chronic rhinosinusitis. BP is an area where additional approval is being pursued.
